Observational Data Analysis in EuroSIDA (MK-0518-058)
Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period
Sponsor: EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)
This observational or N/A phase trial investigates HIV-1 Infections and is currently completed. EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP) leads this study, which shows 13 recorded versions since 2008 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Jun 2022 — Dec 2022 [monthly]
Completed
▶ Show 8 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed
-
Dec 2019 — Jan 2021 [monthly]
Completed
-
Sep 2018 — Dec 2019 [monthly]
Completed
-
Jun 2018 — Sep 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Feb 2017 — Aug 2017 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.